CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

HYDROCHLOROTHIAZIDE; CANDESARTAN CILEXETIL

Inapatikana kutoka:

ALEMBIC PHARMACEUTICALS LIMITED

ATC kanuni:

C09DA06

INN (Jina la Kimataifa):

CANDERSARTAN AND DIURETICS

Kipimo:

12.5MG; 32MG

Dawa fomu:

TABLET

Tungo:

HYDROCHLOROTHIAZIDE 12.5MG; CANDESARTAN CILEXETIL 32MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100

Dawa ya aina:

Prescription

Eneo la matibabu:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0244181002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2014-06-11

Tabia za bidhaa

______________________________________________________________________________
_Candesartan Cilexetil and Hydrochlorothiazide Tablets Product
Monograph Page 1 of 50_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS
candesartan cilexetil and hydrochlorothiazide
tablets
Tablets, 16 mg / 12.5 mg, 32 mg / 12.5 mg and 32 mg / 25 mg, Oral use
House Standard
Angiotensin II AT
1
Receptor Blocker + Diuretic
CANADIAN IMPORTER AND DISTRIBUTOR:
Alembic Pharmaceuticals Canada Ltd.
225 Gibraltar Road, Unit 5
Vaughan, Ontario
L4H 4P9, Canada
MANUFACTURED BY:
Alembic Pharmaceuticals Limited
Alembic Road, Vadodara 390003,
Gujarat, India. Date of Initial Authorization:
June 11, 2014
Submission
Control Number: 259876 Date of Revision: July 22, 2022
______________________________________________________________________________
_Candesartan Cilexetil and Hydrochlorothiazide Tablets Product
Monograph Page 2 of 50_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions – Ophthalmologic
07/2022
7 Warnings and Precautions – Carcinogenesis and Mutagenesis
07/2022
7 Warnings and Precautions – Skin
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
RECENT MAJOR LABEL CHANGES
……………………………………………..……....2
TABLE OF
CONTENTS……………………………………………………………..……....2
PART I: HEALTH PROFESSIONAL INFORMATION
…………………
.
…………
..
…..
4
1
INDICATIONS…………………………………
.
……
.
….……………………..……....4
1.1
Pediatrics….…………………………………..….………………………………..4
1.2
Geriatrics….……………………………………...………………………………..4
2
CONTRAINDICATIONS
…………………………………………………………..…4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................